Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2021 | 2 |
2024 | 1 |
Search Results
3 results
Results by year
Filters applied: . Clear all
Page 1
PQR309, a dual PI3K/mTOR inhibitor, synergizes with gemcitabine by impairing the GSK-3β and STAT3/HSP60 signaling pathways to treat nasopharyngeal carcinoma.
Cell Death Dis. 2024 Mar 30;15(3):237. doi: 10.1038/s41419-024-06615-8.
Cell Death Dis. 2024.
PMID: 38555280
Free PMC article.
Predictive value of a reduction in the level of high-density lipoprotein-cholesterol in patients with non-small-cell lung cancer undergoing radical resection and adjuvant chemotherapy: a retrospective observational study.
Luo F, Zeng KM, Cao JX, Zhou T, Lin SX, Ma WJ, Yang YP, Zhang ZH, Lu FT, Huang Y, Zhao HY, Zhang L.
Luo F, et al.
Lipids Health Dis. 2021 Sep 20;20(1):109. doi: 10.1186/s12944-021-01538-1.
Lipids Health Dis. 2021.
PMID: 34544437
Free PMC article.
Item in Clipboard
Gemcitabine and APG-1252, a novel small molecule inhibitor of BCL-2/BCL-XL, display a synergistic antitumor effect in nasopharyngeal carcinoma through the JAK-2/STAT3/MCL-1 signaling pathway.
Luo F, Lu FT, Qiu MZ, Zhou T, Ma WJ, Luo M, Zeng KM, Luo QY, Pan WT, Zhang L, Xia ZF, Zhang ZH, Cao JX, Zhao HY, Zhang L, Yang DJ.
Luo F, et al.
Cell Death Dis. 2021 Aug 5;12(8):772. doi: 10.1038/s41419-021-04042-7.
Cell Death Dis. 2021.
PMID: 34354046
Free PMC article.
Item in Clipboard
Cite
Cite